Latest Technology Platform News

BlueBet has announced a strategic acquisition of TopSport, supported by a $15 million equity raise, aiming to boost market share and deliver significant earnings accretion by FY26.

Xref Limited reported a solid 10% revenue increase to $10.9 million in H1 FY2025, even as a proposed acquisition by SEEK was narrowly rejected by shareholders. The company plans to continue its growth trajectory as an independent ASX-listed entity with new product launches on the horizon.

Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.

Thrive Tribe Technologies has strengthened its cash position through multiple capital raises and appointed Jade Spooner as its new CEO, while its Slik investment achieved profitability in Q4 2024.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.

Careteq Limited reports solid progress in integrating its Embedded Health Solutions with HMR Referrals, alongside a 14% revenue increase and improved cash flow in Q2 FY25.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.

Origin Energy's December 2024 Quarterly Report reveals a 3% revenue increase in its Integrated Gas segment despite a slight production dip, while Octopus Energy continues rapid customer growth, becoming the UK's largest retailer.

Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.

Weebit Nano has solidified its position in the semiconductor memory sector by signing a major licensing agreement with onsemi and raising A$50 million in capital. The company is well-funded and advancing multiple commercial and technical milestones.

Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.